Otsuka PharmaceuticalTYO: 4578

Actual: Mar 31, 2025

IMPACT-1 Phase 2 met primary endpoint: CAPS-5 -9.64 vs placebo (p=.011); 57% response rate vs 19%; 32% remission vs 12%. No hallucinations, no discontinuations from AEs.

Why it matters: IMPACT-1 is a landmark result — methylone (TSND-201) demonstrated clinically meaningful PTSD efficacy without hallucinogenic effects and with a benign safety profile. The 57% vs 19% response rate and the absence of discontinuations addresses the two main criticisms of the failed MDMA-AT programme (Resilient/Lykos): blinding integrity and tolerability. This data arguably makes TSND-201 the most advanced non-hallucinogenic neuroplastogen in development.

Watch next: EMPOWER-1 Phase 3 interim and topline data

EMPOWER-1 Phase 3 (NCT07456696) recruiting: 300 patients, multi-centre, two active doses vs placebo

Why it matters: Phase 3 is the pivotal registration study. With BTD and strong Phase 2 data, a positive EMPOWER-1 could support an NDA within 2-3 years. Otsuka's resources (maker of Abilify, $15B+ annual revenue) ensure the trial is fully funded.

Watch next: Enrollment completion and topline data readout

Actual: Jul 10, 2025

FDA granted Breakthrough Therapy Designation for TSND-201 (methylone) for PTSD

Why it matters: BTD provides FDA interaction benefits, rolling review eligibility, and organizational commitment. For PTSD, BTD is particularly significant given the MDMA-AT CRL — FDA is signalling openness to a non-hallucinogenic approach with cleaner data.

Actual: Mar 27, 2026

Otsuka announced acquisition of Transcend Therapeutics for $700M upfront + $525M milestones ($1.225B total)

Why it matters: The $1.225B deal is the largest acquisition in the psychedelic/neuroplastogen sector — 20x larger than the Mindset Pharma deal ($59M). It confirms big pharma conviction in non-hallucinogenic neuroplastogens for PTSD. Combined with MSP-1014, Otsuka now has both hallucinogenic (psilocin) and non-hallucinogenic (methylone) approaches — a diversified portfolio strategy.

Watch next: Acquisition close (expected Q2 2026); combined pipeline strategy announcement

Actual: Jun 1, 2023

MHRA approved Phase 2 clinical trial of MSP-1014 for MDD at Clerkenwell Health, UK

Why it matters: MHRA approval for an adaptive Phase 2a/2b design allows dose-finding and efficacy signal detection in a single trial. UK's Clerkenwell Health is one of the premier psychedelic clinical trial sites in Europe.

Watch next: Phase 2 data readout (overdue — study period reportedly ended Oct 2024 but no results published)

Actual: Sep 1, 2023

Otsuka acquired Mindset Pharma for ~CAD $80M (~$59M USD), gaining MSP-1014 and next-gen psilocin prodrug portfolio

Why it matters: First major pharma acquisition of a psilocybin-class drug developer. Otsuka (maker of Abilify/aripiprazole) has deep CNS regulatory expertise. The acquisition gave MSP-1014 big pharma resources for Phase 2 completion and Phase 3 planning.